Literature DB >> 14502281

Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ T-cell responses.

Simona Stäger1, James Alexander, Alun C Kirby, Marina Botto, Nico Van Rooijen, Deborah F Smith, Frank Brombacher, Paul M Kaye.   

Abstract

CD8(+) T cells are essential for long-term, vaccine-induced resistance against intracellular pathogens. Here we show that natural antibodies, acting in concert with complement, are endogenous adjuvants for the generation of protective CD8(+) T cells after vaccination against visceral leishmaniasis. IL-4 was crucial for the priming of vaccine-specific CD8(+) T cells, and we defined the primary source of IL-4 as a CD11b(+)CD11c(lo) phagocyte. IL-4 secretion was not observed in antibody-deficient mice and could be reconstituted with serum from normal, but not Btk immune-deficient, mice. Similarly, no IL-4 response or CD8(+) T-cell priming was seen in C1qa(-/-) mice. These results identify a new pathway by which immune complex-mediated complement activation can regulate T-cell-mediated immunity. We propose that this function of natural antibodies could be exploited when developing new vaccines for infectious diseases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14502281     DOI: 10.1038/nm933

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  80 in total

1.  IL-4 acts as a potent stimulator of IFN-γ expression in CD8+ T cells through STAT6-dependent and independent induction of Eomesodermin and T-bet.

Authors:  Jennifer A Oliver; Valerie R Stolberg; Stephen W Chensue; Philip D King
Journal:  Cytokine       Date:  2011-11-09       Impact factor: 3.861

Review 2.  Natural IgM in immune equilibrium and harnessing their therapeutic potential.

Authors:  Srini V Kaveri; Gregg J Silverman; Jagadeesh Bayry
Journal:  J Immunol       Date:  2012-02-01       Impact factor: 5.422

3.  Therapeutic efficacy of high-dose intravenous immunoglobulin in Mycobacterium tuberculosis infection in mice.

Authors:  Eleanor Roy; Evangelos Stavropoulos; John Brennan; Stephen Coade; Elena Grigorieva; Barry Walker; Belinda Dagg; Ricardo E Tascon; Douglas B Lowrie; M Joseph Colston; Stephen Jolles
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

4.  Hydrophilic Acylated Surface Protein A (HASPA) of Leishmania donovani: Expression, Purification and Biophysico-Chemical Characterization.

Authors:  Manoj Kumar; Kishu Ranjan; Vijay Singh; Chandramani Pathak; Anju Pappachan; Desh Deepak Singh
Journal:  Protein J       Date:  2017-08       Impact factor: 2.371

Review 5.  Antibody-mediated immunomodulation: a strategy to improve host responses against microbial antigens.

Authors:  L Jeannine Brady
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

6.  Immunogenicity of the P-8 amastigote antigen in the experimental model of canine visceral leishmaniasis.

Authors:  E Carrillo; S Ahmed; K Goldsmith-Pestana; J Nieto; Y Osorio; B Travi; J Moreno; D McMahon-Pratt
Journal:  Vaccine       Date:  2006-11-10       Impact factor: 3.641

7.  Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against Leishmania.

Authors:  Blaise Dondji; Eszter Deak; Karen Goldsmith-Pestana; Eva Perez-Jimenez; Mariano Esteban; Sachiko Miyake; Takashi Yamamura; Diane McMahon-Pratt
Journal:  Eur J Immunol       Date:  2008-03       Impact factor: 5.532

Review 8.  Cytokines and their STATs in cutaneous and visceral leishmaniasis.

Authors:  Hannah E Cummings; Rashmi Tuladhar; Abhay R Satoskar
Journal:  J Biomed Biotechnol       Date:  2010-03-15

9.  Complement as an endogenous adjuvant for dendritic cell-mediated induction of retrovirus-specific CTLs.

Authors:  Zoltán Bánki; Wilfried Posch; Asim Ejaz; Verena Oberhauser; Suzanne Willey; Christoph Gassner; Heribert Stoiber; Ulf Dittmer; Manfred P Dierich; Kim J Hasenkrug; Doris Wilflingseder
Journal:  PLoS Pathog       Date:  2010-04-29       Impact factor: 6.823

Review 10.  Complement and its role in protection and pathogenesis of flavivirus infections.

Authors:  Panisadee Avirutnan; Erin Mehlhop; Michael S Diamond
Journal:  Vaccine       Date:  2008-12-30       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.